NCT01777152

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 452 (actual)
• Sponsor: Seagen Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.

Conditions

• Anaplastic Large-Cell Lymphoma
• Non-Hodgkin Lymphoma
• T-Cell Lymphoma

Interventions

Type	Name	Description
DRUG	brentuximab vedotin	1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles
DRUG	doxorubicin	50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
DRUG	prednisone	100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
DRUG	vincristine	1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles
DRUG	cyclophosphamide	750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles

Timeline

• Start date: 2013-01-31
• Primary completion: 2018-08-15
• Completion: 2020-10-02
• First posted: 2013-01-28
• Last updated: 2021-11-30
• Results posted: 2019-07-30

Locations

144 sites across 16 countries: United States, Australia, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Poland, Romania, South Korea, Spain, Taiwan, United Kingdom